UY36574A - Inhibidores de bromodominios - Google Patents

Inhibidores de bromodominios

Info

Publication number
UY36574A
UY36574A UY0001036574A UY36574A UY36574A UY 36574 A UY36574 A UY 36574A UY 0001036574 A UY0001036574 A UY 0001036574A UY 36574 A UY36574 A UY 36574A UY 36574 A UY36574 A UY 36574A
Authority
UY
Uruguay
Prior art keywords
bromodominium
inhibitors
compound
formula
salts
Prior art date
Application number
UY0001036574A
Other languages
English (en)
Spanish (es)
Inventor
Philip G Humphreys
Christopher Roland Wellaway
John Alexander Brown
Katherine Louise Jones
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of UY36574A publication Critical patent/UY36574A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY0001036574A 2015-03-05 2016-03-03 Inhibidores de bromodominios UY36574A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201503720A GB201503720D0 (en) 2015-03-05 2015-03-05 Chemical compound

Publications (1)

Publication Number Publication Date
UY36574A true UY36574A (es) 2016-09-30

Family

ID=52998420

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036574A UY36574A (es) 2015-03-05 2016-03-03 Inhibidores de bromodominios

Country Status (5)

Country Link
AR (1) AR103844A1 (fr)
GB (1) GB201503720D0 (fr)
TW (1) TW201704230A (fr)
UY (1) UY36574A (fr)
WO (1) WO2016139292A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501438B2 (en) 2015-08-11 2019-12-10 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
WO2017024406A1 (fr) 2015-08-11 2017-02-16 Neomed Institute Lactames bicycliques n-substitués, leur préparation et leur utilisation en tant qu'agents pharmaceutiques
EP3334719B1 (fr) 2015-08-12 2021-09-15 Neomed Institute Benzimidazoles substitués, préparation et utilisation de ceux-ci en tant qu'agents pharmaceutiques
WO2017066876A1 (fr) 2015-10-21 2017-04-27 Neomed Institute Imidazopyridines substituées, leur préparation et leur utilisation comme médicaments
US10519151B2 (en) 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
CN109280046B (zh) * 2017-07-21 2021-02-02 浙江海正药业股份有限公司 苯并咪唑类衍生物及其制备方法及其在医药上的用途
CN109384784B (zh) * 2017-08-10 2021-01-12 浙江海正药业股份有限公司 磺酰胺类衍生物、其制备方法及其在医药上的用途
JP2022534472A (ja) * 2019-04-24 2022-08-01 コンバージーン・リミテッド・ライアビリティ・カンパニー 小分子ブロモドメイン阻害剤およびそれらの使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2013097052A1 (fr) * 2011-12-30 2013-07-04 Abbott Laboratories Inhibiteurs de bromodomaine
US20150051208A1 (en) * 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones

Also Published As

Publication number Publication date
AR103844A1 (es) 2017-06-07
TW201704230A (zh) 2017-02-01
WO2016139292A1 (fr) 2016-09-09
GB201503720D0 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
UY36574A (es) Inhibidores de bromodominios
CL2016001889A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1.
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
SV2018005663A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer
CR20150633A (es) Derivados del bipirazol como inhibidores jak
CU20160167A7 (es) Compuestos de pirazolopiridinas y pirazolopirimidinas útiles en el tratamiento de condiciones alérgicas y respiratorias
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
BR112018069612A2 (pt) compostos de pirroltriazina como inibidores de tam
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
ECSP20035222A (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa
SV2018005680A (es) Compuestos de imidazo [4,5-c] quinolin- 2-ona y su uso en el tratamiento del cancer
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
CU20160111A7 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
ECSP20035588A (es) Derivado de amino-metil piperidina como inhibidor de quinasa
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
GT201400089A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
UY36153A (es) ?inhibidores de la fosfoinosítido 3-quinasa delta para su uso en el tratamiento de una enfermedad cutánea inmunoampollosa mediada por autoanticuerpos?
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221104